MedPath

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

Phase 2
Completed
Conditions
Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome
Registration Number
NCT00215566
Lead Sponsor
Dynogen Pharmaceuticals
Brief Summary

This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Subjects must have a history of IBS-c for at least 3 months prior to randomization as assessed using ROME criteria
  • Must have had endoscopic/radiologic bowel evaluation within the past 10 years
  • Must comply with completing a daily diary and be able to comply with GI transit measurements, including swallowing capsules containing small x-ray visible markers
  • Female subjects cannot be pregnant, post-partum for less than 1 year or breastfeeding
Exclusion Criteria
  • Serious underlying diseases, including psychiatric disorders
  • Current history of conditions affecting bowel transit
  • Recent history of biochemical or structural abnormalities of the gastrointestinal tract, gastrointestinal surgery, or gastrointestinal infection
  • Clinically significant abnormal examination findings or laboratory tests
  • Inability to stop taking certain medications, or a planned change in medications (including herbal remedies) which could interfere with study assessments
  • Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome
  • Presence of a medical condition which could interfere with the interpretation of study data
  • Significant use of nicotine or caffeine

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Evaluation of the effect of DDP733 on gastrointestinal transit
Secondary Outcome Measures
NameTimeMethod
Evaluation of the effect of DDP733 on patient reported outcomes

Trial Locations

Locations (13)

Hopital St-Sacrement

🇨🇦

Quebec, Canada

London Road Diagnostic Clinic

🇨🇦

Sarnia, Ontario, Canada

St Paul's Hospital

🇨🇦

Vancouver, British Columbia, Canada

Hys Medical Centre

🇨🇦

Edmonton, Alberta, Canada

Sarnia Institute of Clinical Research

🇨🇦

Sarnia, Ontario, Canada

Hotel Dieu Hospital

🇨🇦

Kingston, Ontario, Canada

Canadian Phase Onward Inc.

🇨🇦

Toronto, Ontario, Canada

Meadowlands Family Health Centre

🇨🇦

Ottawa, Ontario, Canada

Toronto Digestive Disease Associates, Inc

🇨🇦

Toronto, Ontario, Canada

Surrey GI Clinic

🇨🇦

Guelph, Ontario, Canada

St. Joseph's Healthcare

🇨🇦

London, Ontario, Canada

McMaster University Medical Centre

🇨🇦

Hamilton, Ontario, Canada

QE II Health Sciences Centre

🇨🇦

Halifax, Nova Scotia, Canada

© Copyright 2025. All Rights Reserved by MedPath